Key result
High-pressure retrograde AIV injection of FGF-2 increases LAD protein retention ~88% vs intracoronary delivery.
Why the study?
Delivery of angiogenic factors to ischemic myocardium remains a practical challenge, motivating evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein.
Does high-pressure retrograde injection of FGF-2 into the AIV improve protein retention and myocardial blood flow in a porcine model of chronic myocardial ischemia?
Does high-pressure retrograde injection of FGF-2 into the AIV improve protein retention and myocardial blood flow in a porcine model of chronic myocardial ischemia?
Absolute Event Rate: 1.2% vs 0.64%
p-value: p=0.03
High-pressure retrograde injection into the AIV improves myocardial retention of FGF-2 and preserves resting myocardial blood flow compared to control in a porcine model of chronic ischemia.
Enhanced retention via retrograde AIV injection warrants further preclinical testing; should not yet influence clinical practice in myocardial ischemia.
Delivery of angiogenic factors to ischemic myocardium remains a practical challenge. We evaluated the efficiency and efficacy of delivery of fibroblast growth factor-2 (FGF-2) protein via high-pressure retrograde injection into the anterior interventricular vein (AIV) in a porcine model of chronic myocardial ischemia. Labeled FGF-2 protein was delivered to the myocardium of three pigs via the AIV and the left anterior descending (LAD) coronary artery in three others. At 1 hr, the amount of protein in the left ventricle and the LAD region was quantified. Copper stents were implanted in the LAD of 25 pigs, resulting in chronic myocardial ischemia. At 4 weeks, microsphere-derived myocardial blood flow was assessed at rest and during pacing. In eight pigs (AIV FGF), FGF-2 protein (6 microg/kg) was delivered via high-pressure retrograde injection into the AIV. Six pigs (intracoronary FGF) received the same amount of FGF-2 by intracoronary delivery. Five pigs (AIV saline) received a placebo injection into the AIV and six pigs (control) served as controls. Four weeks later, myocardial blood flow was reassessed. At 1 hr, significantly more FGF remained in the left ventricle (1.3 vs. 0.82 microg; P < 0.04) and in the LAD region (1.2 vs. 0.64 microg; P = 0.03) after AIV compared to intracoronary delivery. Four weeks after treatment, resting LAD blood flow (normalized to right ventricular flow) improved slightly in the AIV FGF and intracoronary FGF arms (1.32-1.37 for both; P = 0.11), while it decreased significantly in the AIV saline (1.32-1.23; P = 0.02) and the control arms (1.32-1.19; P = 0.0004). Pacing LAD blood flow decreased significantly in the control arm (1.30-1.23; P < 0.05), but did not change significantly in the other three arms. High-pressure retrograde injection into the AIV may represent an efficient and effective means for delivering angiogenic factors to ischemic myocardium.
No takes yet. Share an insight, caveat, or question.
Fearon et al. (2004) studied Chronic myocardial ischemia (n=31). High-pressure retrograde injection of FGF-2 protein into the anterior interventricular vein vs. Intracoronary delivery of FGF-2, AIV saline, and control was evaluated on FGF protein remaining in the LAD region at 1 hr (p=0.03). High-pressure retrograde injection of FGF-2 into the anterior interventricular vein increased protein retention in the LAD region at 1 hour compared to intracoronary delivery (1.2 vs. 0.64 microg; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: